Home Browse Update Summary

This process involves analyzing complex genetic data and may take a moment.

Return Search

PDX ID	27.2A
Host Strain(and Source)	NSG Source: Monash University
Host Strain Immune system Humanized	NO
Host Type	Testosterone supplemented
Graft Site	Subcutaneous
Current Generation (* indicates number of generations grown in Castrate host)	31
Average PDX Generation Time (days +/- SEM)	53 ± 6
Tumour preparation	Tumor solid
Tumour Characterization Technology	Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq
Tumour confirmed not to be of Mouse/EBV origin	Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC
Passage QA performed	Routine QA every 2-3 passages
Associated meta data
PDX model availability	Yes (fixed, frozen)
Governance restriction for distribution	Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements
Pubmed ID	34413304; 30049486

This heatmap displays the call type of curated CNVs in the presented samples.

This heatmap displays the call type of CNVs in commonly occurred samples.

This table displays curated CNVs

PDX ID	Gene Symbol	CNV Log2	CNV Copy	CNV Call	Experiments name	Platform	Reference genome
27.2A	MET	0.899	3.730	Gain	MURAL Prostate Cancer PDX collection	Targeted GARVAN Panel	hg19
27.2A	BRAF	0.899	3.730	Gain	MURAL Prostate Cancer PDX collection	Targeted GARVAN Panel	hg19
27.2A	EZH2	0.899	3.730	Gain	MURAL Prostate Cancer PDX collection	Targeted GARVAN Panel	hg19
27.2A	KMT2C	0.899	3.730	Gain	MURAL Prostate Cancer PDX collection	Targeted GARVAN Panel	hg19
27.2A	CHD7	0.865	3.642	Gain	MURAL Prostate Cancer PDX collection	Targeted GARVAN Panel	hg19
27.2A	MYC	0.865	3.642	Gain	MURAL Prostate Cancer PDX collection	Targeted GARVAN Panel	hg19
27.2A	CDH1	-1.088	0.941	Loss	MURAL Prostate Cancer PDX collection	Targeted GARVAN Panel	hg19
27.2A	FANCA	-1.316	0.803	Loss	MURAL Prostate Cancer PDX collection	Targeted GARVAN Panel	hg19
27.2A	AR	-4.026	0.061	GSR	MURAL Prostate Cancer PDX collection	Targeted Twist Panel	hg19
27.2A	CHD1	-13.394	1.858e-04	Homdel	MURAL Prostate Cancer PDX collection	Targeted GARVAN Panel	hg19
27.2A	RB1	-19.432	2.830e-06	Homdel	MURAL Prostate Cancer PDX collection	Targeted GARVAN Panel	hg19

Sample Number	27.2A
Sample Site	Inguinal lymph node
Sample source	Autopsy
Pathology Tumour Diagnosis	Adenocarcinoma
Gleason Score	None
Primary Gleason Score	None
Secondary Gleason Score	None
Tertiary Gleason Score	None
ISUP Grade Group
Tumour Grade
D'Amico Risk Classification
Tumour Volume (in cc)	0.0
Treatment Prior to Specimen Collection	ADT, docetaxel, abiraterone

Patient Number	27
Sex	Male
Diagnosis	Prostate Cancer
PSA at diagnosis (ng/mL)	42
Consent to share data	Yes, subject to ethical review

Patient Tumour Collection (Current Model)
Tumour sample ID	27.2A
Patient Age (binned in 5 year age groups)	70-74

This heatmap displays the mutations of curated sequence variants.

This table displays curated sequence variants

PDX ID	Gene Symbol	Total Read Depth	Alternate Frequency	Consequence	Exon	GnomAD AF	CADD PHRED score	ClinVar significance	Platform	Experiments Name	Reference	Library Type	Instrument Type
27.2A	PCDH11X	187	1.0	Missense variant	'2/7	.	22.9	-	Targeted GARVAN Panel	MURAL Prostate Cancer PDX collection	hg19	paired	Illumina HiSeq 2500
27.2A	TH	69	0.71	Start lost	'1/14	.	21.5	-	Targeted GARVAN Panel	MURAL Prostate Cancer PDX collection	hg19	paired	Illumina HiSeq 2500
27.2A	TH	69	0.71	Start lost	'1/14	.	21.5	-	Targeted GARVAN Panel	MURAL Prostate Cancer PDX collection	hg19	paired	Illumina HiSeq 2500
27.2A	SON	125	0.5	Missense variant	'3/12	.	25.4	-	Targeted GARVAN Panel	MURAL Prostate Cancer PDX collection	hg19	paired	Illumina HiSeq 2500
27.2A	AR	—	—	GSR	—	—	—	—	Targeted Twist Panel	MURAL Prostate Cancer PDX collection	hg19	paired	NextSeq 500

No information in Drug dosing Table